A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Abstract

The results of this study indicated imatinib had minimal activity as a single agent in EOC. Its ability to modulate its molecular targets suggests that it may be considered in combinatorial therapy.